Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic, Inc.

MyoSure NL

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives.

None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities.

What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses.

We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes.  
To view our community guidelines, visit: www.hologic.com/social-media

Ascent Venture Partners

Reminder! Join Dr. Soyini Hawkins tomorrow, December 13 at 8 p.m. ET / 5 p.m. PT for an Acessa Patient Selection webinar.
Register now: https://bit.ly/3Qd17N6 #Hologic #FibroidAwareness

Join us at ASLM in Cape Town, South Africa from 12-15 December.

Find us at Booth 2, to meet our experts and learn more about our multi-disease testing capabilities and how our extensive portfolio of assays help you meet your lab's growing needs.
Our molecular testing portfolio is designed to bring clinical confidence and workflow efficiency to labs and clinicians whilst guiding patient care and enabling early detection. 

Are you attending?

We are proud to be recognized for the third consecutive year as one of America’s Most Responsible Companies by Newsweek! As a purpose-driven organization championing the health of women, their families and their communities, our employees work every day to be a global force for good. #WhyHologic https://ow.ly/lQV550QgYnr

Meet Gianluca, who is part of our diagnostics team in Italy. He explains how working at Hologic comes with a feeling of connection and belonging with his colleagues thanks to their shared dedication to enabling healthier lives. #WhyHologic

Our dedication to the fight against HIV and AIDS goes back to the 1990s when the National Heart, Lung, and Blood Institute (NHLBI) approached us to develop a nucleic acid blood screening test for the detection of HIV. Today, our cutting-edge HIV detection technology can help patients even more: https://bit.ly/49tsgDf #HIVAwarenessMonth

Join us on Monday, December 11th at 10am ET for “Access Across America: A Year-End Reflection on Women’s Health Policy.” This webinar hosted by our Director of Government Affairs Mia Keeys, will feature a panel of leading women’s health and policy experts reflecting on the developments of the past year and discussing what’s in store for 2024, with a special focus on rural and underserved communities across the United States. Register here: https://bit.ly/49YEV0W

NASDAQ:HOLX

Hologic

Last Close

75.91

03/05 20:00

Market Cap

17.47B

Beta: 1.00

Volume Today

2.07M

Avg: 1.32M

PE Ratio

33,459.20

PFCF: 19.40

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics